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http://www.biomedcentral.com/1471-2334/14/154RESEARCH ARTICLE Open AccessHow do hospital professionals involved in a
randomised controlled trial perceive the value of
genotyping vs. PCR-ribotyping for control of
hospital acquired C. difficile infections?
Ala Szczepura1,2*, Susan Manzoor3, Katherine Hardy4,5, Nigel Stallard1, Helen Parsons1, Savita Gossain5
and Peter M Hawkey4,5Abstract
Background: Despite scientific advances in typing of C. difficile strains very little is known about how hospital staff
use typing results during periods of increased incidence (PIIs). This qualitative study, undertaken alongside a
randomised controlled trial (RCT), explored this issue. The trial compared ribotyping versus more rapid genotyping
(MLVA or multilocus variable repeat analysis) and found no significant difference in post 48 hour cases (C difficile
transmissions).
Methods: In-depth qualitative interviews with senior staff in 11/16 hospital trusts in the trial (5 MLVA and 6
Ribotyping). Semi-structured interviews were conducted at end of the trial period. Transcripts were content analysed
using framework analysis supported by NVivo-8 software. Common sub-themes were extracted by two researchers
independently. These were compared and organised into over-arching categories or ‘super-ordinate themes’.
Results: The trial recorded that 45% of typing tests had some impact on infection control (IC) activities.
Interviews indicated that tests had little impact on initial IC decisions. These were driven by hospital protocols
and automatically triggered when a PII was identified. To influence decision-making, a laboratory turnaround
time < 3 days (ideally 24 hours) was suggested; MLVA turnaround time was 5.3 days. Typing results were predominantly
used to modify initiated IC activities such as ward cleaning, audits of practice or staff training; major decisions (e.g. ward
closure) were unaffected. Organisational factors could limit utilisation of MLVA results. Results were twice as likely to be
reported as ‘aiding management’ (indirect benefit) than impacting on IC activities (direct effect). Some interviewees
considered test results provided reassurance about earlier IC decisions; others identified secondary benefits on
organisational culture. An underlying benefit of improved discrimination provided by MLVA typing was the ability
to explore epidemiology associated with CDI cases in a hospital more thoroughly.
Conclusions: Ribotyping and MLVA are both valued by users. MLVA had little additional direct impact on initial
infection control decisions. This would require reduced turnaround time. The major impact is adjustments to earlier IC
measures and retrospective reassurance. For this, turnaround time is less important than discriminatory power. The
potential remains for wider use of genotyping to examine transmission routes.
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Clostridium difficile infection (CDI) is a major cause of
hospital acquired infections (HAIs). Early detection and
control of CDI is essential to reduce the likelihood of
cross-infection and prevent serious outbreaks. The de-
velopment of more rapid and discriminatory typing tests
should improve infection control (IC). However, the
evaluation of diagnostic tests is recognised to be com-
plex, including technical, clinical and organisational di-
mensions [1,2]. The Diagnostic Assessment Programme
recently established by the National Institute for Health
and Care Excellence (NICE) also highlights the need for
qualitative evidence on the experiences of staff who use
new tests [3].
CDI occurs in patients in whom the normal gut flora
have been destroyed, usually after use of a broad spectrum
antibiotic. Patients undergoing general surgery [4], oncol-
ogy patients [5,6] and those with chronic renal disease [7]
are at particular risk of becoming infected during a hos-
pital stay. C. difficile infection can be life-threatening, es-
pecially in elderly patients. Because of its long incubation
period it is not always easy to determine with accuracy the
origin of transmission or contamination [8-10]. On a hos-
pital ward, the first indication of possible CDI transmis-
sion is a period of increased incidence (PII) or CDI cluster
which, if not controlled, can turn into a serious outbreak.
The United Kingdom (UK) Department of Health defines
a PII as two or more new cases occurring on a ward
(>48 hours post admission, but not relapses) in a 28-day
period; an outbreak is defined as two or more cases caused
by the same strain [11].
Determining whether transmission has occurred is es-
sential for tracing of linked cases and effective infection
control. This requires some means of typing strains to
confirm whether cases are in fact linked. The discrimin-
atory ability of a test is crucial in defining whether a sec-
ond isolate is part of an outbreak or a sporadic infection.
There are a variety of techniques that can be used to
type C. difficile strains. PCR-ribotyping was the first
method to gain widespread acceptance for this purpose
[12]. In the UK, the Health Protection Agency (HPA)
established a C. difficile Ribotyping Network in 2007 to
provide a typing service for NHS hospital trusts. How-
ever, PCR-ribotyping may not provide enough discrim-
inatory power to fully characterise C. difficile strains.
Therefore, in 2008 the HPA introduced a new service
to provide ‘enhanced fingerprinting’ of C. difficile for NHS
hospitals [13]. Access to this service was strictly controlled,
in the first instance by regional microbiologists, due to its
cost and the need to balance availability with the scale of
the challenge. The test used to provide this more detailed
‘fingerprint’ or genotyping information is multilocus vari-
able repeat analysis (MLVA), sometimes termed multi
locus variable number tandem-repeat (VNTR) analysis[14]. The MLVA test has a greater discriminatory ability
than most other fingerprinting methods for analysing
closely related C. difficile strains [15].
The epidemiology of C. difficile has changed with the
emergence of new, virulent strains such as ribotype ‘027’
[16]. This has been associated with larger hospital out-
breaks and more severe disease, resulting in a much
higher mortality rate and increased risk of complica-
tions, as well as more recurrent infections or relapses.
Typing of these more virulent strains is essential in
order to correctly differentiate outbreaks with the poten-
tial for serious consequences from apparently related
clusters. MLVA can distinguish more than 20 sub-types
of ‘027’, now one of the more commonly occurring C.
difficile ribotypes [17]. Importantly, the method can also
provide a high level of discrimination among other im-
portant epidemic C. difficile ribotypes, including ribotypes
‘001’ and ‘106’. Together with ‘027’, these accounted for
approximately 70% of C. difficile isolates ribotyped by the
NHS in 2007-08 [18]. Since 2009, National Health Service
(NHS) hospital trusts have had to report every CDI out-
break to their local primary care trust (PCT) or strategic
health authority (SHA); they may incur a fine of up to
£50,000 if they are found to have breached hygiene regula-
tions [19]. UK hospitals are also expected to subject out-
breaks to a resource-intensive, root cause analysis in order
to highlight any factors which might be linked to trans-
mission and to take appropriate preventative and precau-
tionary steps [20].
Infection control (IC) measures to manage CDI clus-
ters necessitate a complex range of decisions to address
staff behavioural aspects as well as organisational factors
[21]. It has been argued that, without more discrimin-
atory information on strains, hospital staff may incor-
rectly assume they have a CDI outbreak and may
institute unnecessary and expensive IC procedures. In
contrast, if typing can confirm that transmission has
taken place, this may facilitate more timely IC measures
and reduce the number of further cases. At present,
there is a paucity of research evidence to indicate the de-
gree to which typing results actually influence hospital
staff in their infection control decisions or what the
added benefits of more discriminatory MLVA informa-
tion are when dealing with clusters of cases.
The present qualitative study was undertaken alongside a
randomised controlled trial (RCT) set up to measure the
differential impact on hospital CDI rates of MLVA typing
versus standard ribotyping [22]. The trial demonstrated no
significant difference between MLVA and control group in
terms of a reduction the number of post 48 hour cases of
C difficile. The qualitative study collected in-depth qualita-
tive data from senior hospital staff on the use of genotyping
and ribotyping information for control of hospital acquired
infections during periods of increased CDI incidence.
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A total of sixteen hospitals were recruited to the main
trial. All PIIs were identified and isolates sent for typing
by MLVA or PCR-ribotyping. A ‘test-impact’ data collec-
tion form was attached to each typing result returned
(see Additional file 1). This short questionnaire re-
quested information on whether, as a consequence of
the typing information, any infection control actions
were initiated, or whether any actions had been stopped.
The questionnaire also asked respondents to categorise
the degree to which each typing result had aided infec-
tion control management (strongly agree, agree, dis-
agree, strongly disagree). Hospitals involved in the trial
followed their own protocols for initial identification of
C. difficile toxin-positive patients and subsequent infec-
tion control procedures for CDI [22].
A qualitative study was undertaken alongside the main
trial in order to explore test utilisation in greater detail.
All hospital trusts recruited to the RCT were invited to
take part in the study. Lead microbiologists in each trust
were sent an information sheet about the study and
asked whether they, or another suitable member of the
hospital’s infection control staff, would be prepared to
be interviewed. Interview trusts were selected using
maximum variation sampling to ensure that their char-
acteristics were representative of the whole trial popula-
tion [23]. The final sample comprised eleven trusts
covering a total of 20 hospitals.
A topic guide (Table 1) was developed based on ana-
lysis of test-impact forms and piloted before use. Inter-
viewees were sent the topic guide prior to interview
together with a breakdown of their trust’s test-impactTable 1 Interview topic guide
Interview topics Questions to ask
Ribotyping history When first offered a ri
Benefits of ribotyping
Weaknesses of a ribot
MLVA typing service Has/would access to m
What factors, if any, ha
Initiating ward closures You reported XX ward
Explain decision-makin
How has/could ribotyp
Initiating extra cleaning You reported XX insta
Explain decision-makin
How has/could ribotyp
Stopping ward closures/extra cleaning Value (if any) of riboty
How ribotyping/MLVA
Changes to audits of practice/staff training Please explain decision
How has/could ribotyp
Other changes Changes which couldresponses over the time period of the trial (April 2010-
April 2011). The qualitative study was conducted at the
end of the trial period (July-September 2011) in order
not to influence trial outcomes. Participants were free to
choose the date and time for their interview. All inter-
views were undertaken by the same person (a senior
researcher with over twenty years’ experience of evalu-
ating diagnostic tests). Interviews, which lasted 45 –
90 minutes, were audio-taped with the participants’
consent and later transcribed verbatim. Each partici-
pant was allocated a study number to ensure confiden-
tiality. Additional notes on the interviews were taken
by the interviewer.
Transcripts were analysed using framework analysis
[23] supported by NVivo-8 software package [24]. Two
researchers examined the material using a qualitative
thematic approach (the senior researcher and an experi-
enced qualitative researcher). Analysis involved compar-
ing different interviewee’s accounts with one another,
and coding responses into recurring themes capable of
accommodating all the data [25]. Close analysis of the
transcript data identified a number of sub-themes. These
were then grouped under a number of over-arching cat-
egories or ‘super-ordinate themes’. In cases where the re-
searchers failed to agree either the categorisation was
discussed until agreement was reached or the coding
frame was modified to accommodate the new data. At
this stage of the analysis sub-themes might exhibit ele-
ments which meant they could be placed in more than
one category, indicating the inter-relatedness of some
themes. In these cases, one super-ordinate theme was
identified and, if necessary, certain elements of thebotyping service
when dealing with periods of increased CDI incidence
yping service
ore rapid MLVA information be of added benefit and, if so, how?
ve limited value of MLVA information? (MLVA Group only)
closures as a result of ribotyping/MLVA typing result
g process for initiating a ward closure.
ing/MLVA typing influenced decision-making in this area
nces of extra cleaning as a result of ribotyping/MLVA typing
g process for initiating cleaning changes.
ing/MLVA typing influenced decision-making in this area
ping/MLVA typing in preventing ward closures or changes in cleaning
typing influences decision-making
-making process in the areas of audits of practice and staff training.
ing/MLVA typing influenced decision-making in these areas
improve value of typing information further in infection control and why
Szczepura et al. BMC Infectious Diseases 2014, 14:154 Page 4 of 18
http://www.biomedcentral.com/1471-2334/14/154sub-theme and the associated quotations were assigned
to a different sub-theme. Theoretical saturation was
considered to have been reached once no new theme
emerged [23].
The research study was carried out in compliance with
the Helsinki Declaration (http://www.wma.net/en/30pub
lications/10policies/b3/index.html). Ethical approval was
received on 08/01/2010 (reference number 10/H1202/3)
from the Black Country Research Ethics Committee which
had UKCRN approval; R & D approval for all 16 trusts
was also obtained.
Results
Characteristics of interview sample
Eleven hospital trusts agreed to participate in the quali-
tative study; five were in the intervention group and had
experience of MLVA and PCR-ribotyping and six were
control sites with experience of ribotyping only. Hospi-
tals identified 15 staff who performed an infection con-
trol role in their trust for interview. These included
eight directors of infection prevention/control, six con-
sultant microbiologists and one nurse member of the
hospital infection control team. Table 2 shows that the
trusts in which individuals were located were representa-
tive of the whole trial population in terms of size (num-
ber of beds) and on-site access to hospital isolation
facilities.
Table 3 provides an overview for the whole trial popu-
lation in terms of the types of effects reported on trial
test-impact forms. Overall, 16% of tests were reported to
lead to additional cleaning measures, 12% to further au-
dits of practice and 12% to additional staff training. The
activity most often stopped was a planned audit of prac-
tice (20% of tests), followed by cleaning (10% of tests).
Test-impact response patterns for trusts recruited to the
qualitative study were similar to those reported by all
the trusts in the trial.
The two trial groups exhibited no difference in time
from PII to receipt of samples in the typing laboratory
(14.0 and 14.4 days for control and MLVA groupTable 2 Characteristics of trusts participating in interviews vs
Inte
MLVA
Number Trusts Interviewed 5
Hospital isolation facilities
Average bed size 1,056
Single rooms with en-suite (% total beds) 10%
Single rooms without en-suite (% total beds) 10%
Average typing test requests over 12 months
Test requests (mean number/trust) 56.0
All post 48 hr C difficile cases reported over 12 monthsrespectively). However, laboratory turnaround time was
significantly shorter for MLVA samples (5.3 days com-
pared to 13.6 days for PCR-ribotyping; p < 0.001).
Common themes emerging from interviews
An overview of the sub-themes drawn out from the tran-
script material is presented in Table 4. These were orga-
nised under four super-ordinate themes. Interviews
focused on the factors which influenced infection control
measures in their trusts and the added value of typing re-
sults when dealing with PIIS. In addition, intervention
trusts were asked to consider their experiences of MLVA
and compare this with the previous ribotyping service. In
the PCR-ribotyping group, interviewees were asked what
they considered might be the benefits of access to more
rapid and discriminatory MLVA typing.
Theme 1: context
In all interviews, the changing context was highlighted as
an important factor influencing approaches to CDI con-
trol, with three main underlying sub-themes emerging.
Sub-theme: fall in numbers of CDI cases Interviewees
in both groups (MLVA and ribotyping) commented on a
recent fall in UK numbers of CDI cases. This was per-
ceived to have had both positive and negative impacts. It
had made control of CDI more manageable in the trust
while, at the same time, reducing the usefulness of typ-
ing tests because the hospital was no longer faced with
such a large number of PIIs:
It sort of falls into two time frames… One where we
were clearly dealing with higher numbers than we are
now, in which case it [typing] was really quite useful. I
think the past 12 or 18 months it’s become much
less so…because the incidence has fallen considerably
[4: Ribotyping Trust].
Set against this general trend of falling CDI numbers, an
increase in faecal samples sent to the hospital laboratory. all trial trusts
rview group Trial population All trusts
in trialRibotyping MLVA Ribotyping
6 NA NA NA
977 922 912 902
10% 14% 13% 12%
6% 10% 7% 5%
61.5 66.8 58.6 50.4
814 868 1,682
Table 3 Direct impact of typing test results on infection control (IC) activities*
Impact on infection
control activity
Percentage typing
results reporting effect (%)
Type of effect reported** (% all typing results)
Cleaning Ward
closure
Audit of
practice
Staff
training
All IC activities 45 26 2 32 13
IC activity started 23 16 2 12 12
IC activity stopped 23 10 0 20 1
*Reported in 244 test-impact data collection forms attached to typing results over period April 2010 – April 2011 (120 ribotyping & 124 MLVA).
**More than one type of change may be recorded per test-impact form.
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ground number this could lead to an apparent rise in CDI
incidence which was confusing. Factors mentioned in in-
terviews included audits by infection control teams which
led to apparent increases in the number of CDI cases in a
hospital:
[infection control nurses] remind them to send
samples and then, you know, you get more samples,
and you get more positives, and it’s almost a vicious
circle. So I think there’s some sort of false clustering
as well which makes things very, very confusing
[5: Ribotyping Trust].
At the same time, a decrease in overall CDI incidence
did not necessarily lead to resource savings because the
remaining cases might now be explored in greater detail:
I think that’s what happened is that the numbers of
cases of C. diff have dropped, so the amount of timeTable 4 Thematic categories & associated sub-themes from in
Super-ordinate theme Descriptor
1 Context Internal trends and changes in external environm
2 Test process Factors associated with the test itself which inhib
utilisation of typing test results in the hospital
3 Infection control Interface between typing test result and specific
4 Indirect benefits Effects not related directly to individual cases, incwe have put into each area, or each case, is
substantially more [27: MLVA Trust].
Sub-theme: Low transmission rates Almost all inter-
viewees pointed out that typing had identified that most
PIIs did not involve linked cases, with 72% of PIIs in the
trial (a similar percentage in both arms) shown not to be
related. A growing expectation that this would be the
case was considered to have influenced the value of typ-
ing information in decision-making:
Well I think it’s been fascinating because our results
have shown that clusters of similar types almost
never occur… I’d have said that by chance we
should have had more the same than we had – they
are always different.…I mean I can’t give you the
exact figure, but the number of times they’ve come
back the same has been so small it’s almost as if,
you know how Gregor Mendel fixed his result, I’d
have said by chance we should have had more that-depth interviews
Containing these sub-themes
ent a) Fall in numbers of CDI cases
b) Low transmission rates
Requirement to report outbreaks
it or facilitate a) Routine hospital protocols
b) Timing of results
c) Optimum lab turnaround time
d) Process time in hospital
e) More discriminatory typing information
f) Understanding MLVA results
g) Confidence in MLVA results
Organisation of typing test requests
infection control measures a) Ward cleaning
b) Ward closure
c) Audit of practice
Staff training
luding potential benefits a) Organisational culture
b) Reassurance/confidence building
Epidemiological value
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different [2: Ribotyping Trust].
I think there was only one occasion where I think we
had similar VNTR [MLVA] type on … one of our
wards. Two cases, but apart from that most of the
time anyway we have sent stuff over to you then it
came back as different ones. [17: MLVA Trust]
no I suppose the only thing, pragmatically now is that
the numbers we’re dealing with are now so low that it’s
almost not of academic interest. I mean just looking
back at this month we’ve had three hospital attributable
cases of C. diff, three different wards, probably two of
them well came in with it [104: Ribotyping Trust].Sub-theme: requirement to report outbreaks Because
more discriminatory MLVA tests identified fewer cases as
linked, trusts perceived this as of direct financial benefit.
This reduction in the number of outbreaks identified meant
that fewer had to be reported to the PCT or SHA. In its
turn, this reduced the trust’s exposure to possible fines:
Obviously if they [PIIs] are outbreaks then PCT come
into action and then we send the reports. So if the PII is
not confirmed as an outbreak it’s a bit of a [financial]
relief to us. … Especially when .. at the end of the year we
calculate how many PIIs we declared how many were
outbreaks. Last year we had 50% reduction in outbreaks
- more than 50% reduction [22: MLVATrust].
Equally important, it could also reduce the hospital’s
workload because effort was not wasted unnecessarily
on non-serious incidents:
…and if it’s called a definite PII then it becomes a
serious incident, ‘serious untoward incident’. That gets
reported to the SHA and the SHA would like to report
all of these as serious but it’s a lot of work. We would
like to know what the typing is first before, before you
escalate. Because otherwise you give them a whole
load of things but then you have to de-escalate and it’s
an awful lot of work for our risk team [66: Ribotyping
Trust].Theme 2: test process
Inevitably, infection control decisions are complex and
do not depend solely on typing test information. Inter-
viewees were asked to describe the degree to which
typing results actually influenced their management of
PIIs or CDI clusters. They were asked to consider any
factors, including test characteristics, which had lim-
ited or enhanced this impact.Sub-theme: routine hospital protocols Interviewees
considered that the initial decision of whether to initiate
infection control measures could not be directly driven by
typing results. Instead, both groups reported that once a
PII was identified in their organisation, control measures
were triggered by pre-existing hospital protocols. This was
viewed as inevitable in a situation where test turnaround
time could be longer than average patient length of stay:
We’ve instituted a much more standard approach…..
we use this horrible phrase ‘special measures’ so that
we actually put heightened infection prevention input
into a ward where we have two cases within a 28 day
period irrespective of what the ribotyping ultimately
reveals which is why …. the answer to the
questionnaire has always been ‘no it hasn’t made any
difference’ [12: Ribotyping Trust].
In some situations, control measures might even start
with the first confirmed case, rather than waiting for a
PII because ICD numbers were now so low. This could
further limit the direct impact of typing:
Whenever we test if there’s a positive on any of them we
react exactly the same way. So we inform the ward, we
inform the consultant, yep, we’ll do an RCA [root-cause
analysis], and because we’re at the numbers now where
we can you know do a meaningful RCA on each one…..
we’ll do a full root-cause analysis [37: MLVATrust].
And what we tend to do now is we have what we
call a ‘slice of PII’ here. Which is you have a single
case what we do is we go down at that stage and
check the ward environment, then cleaning it
triggers an automatic intervention to try and go
and see if there are any things that we should be
worried about at that stage. Because if we’ve got a
case we want to make sure that our standards are
high, although it might be too late. Then if we get
two cases we automatically go and review
everything and we do a terminal clean of the ward
[100: MLVA Trust].
When we’ve got someone who’s got C. diff then they’re
a very high priority to get a side room and that side
room is cleaned daily with Actichlor Plus and then
ideally we’ve got in our plan once a week the C. diff
patients in a side room are moved to another side
room, and the side room moved from gets cleaned with
hydrogen peroxide. [43: MLVA Trust].
Sub-theme: timing of results All interviewees identified
laboratory turnaround time as the main factor limiting
the direct use and value of typing results. This was
Szczepura et al. BMC Infectious Diseases 2014, 14:154 Page 7 of 18
http://www.biomedcentral.com/1471-2334/14/154true for MLVA as well as for the slower ribotyping
service:
You’d usually make your decision and then when the
ribotyping comes back, hopefully, it would confirm that
you’d done the right thing [11: Ribotyping Trust].
If we get real time, I mean … if I could get the help
quickly, urgently then probably it would really help for
making those decisions really. … Because um even
though this service was quick, it’s not quick enough to
sort the things out [48: MLVA Trust].
In terms of how it actually helps us manage the
outbreak, it doesn’t help us in real-time because we don’t
get the results back in real-time [6: Ribotyping Trust].
I think the information obviously is not timely enough
..yes it’s a retrospective system [7: Ribotyping Trust].
The time taken for typing the more rare ribotypes
could prove to be quite lengthy:
The other [thing] was the delay for some of the rarer
ribotypes. So we actually had a couple of instances
where um we were anxious, the people I think
rather than me, were anxious to be reassured
whether these were or not the same um and we
couldn’t provide them with that information
because of the delay [97: Ribotyping Trust].
Interestingly, some interviewees reported that, over
time, there was a growing confidence that CDI cases
would prove not to be linked. This had reduced the per-
ceived need for rapid typing information. Instead, results
were used to provide reassurance:
I suppose initially the main weakness was the time
delay in getting the results back…..as this has gone on
we have come to be, I don’t know, maybe falsely
confident that they won’t be the same so it doesn’t really
matter that it takes a bit of time [8: Ribotyping Trust].
But most of the time it turns out to be different VNTR
[MLVA] types. So it was quite useful to reassure
ourselves that it’s not a problem with you know …
most might be sporadic cases really [45: MLVA Trust].
Other interviewees remembered examples where a
typing result had surprised them, but the turnaround
time had limited its usefulness:
…and to my surprise you know when we got the result
back there did seem to be on-going transmission
and that really focused management. But it wouldhave been so much nicer to have been more timely
[57: Ribotyping Trust].
Sub-theme: optimum lab turnaround time When asked
to identify an ideal laboratory turnaround time, most
interview subjects selected somewhere in the range
2-3 days. The average turnaround time recorded for
the MLVA test (5.3 days) was nearly double the upper
limit; and the 13.6 days recorded for ribotyping dur-
ing the trial was almost five times higher:
I don’t think it does need to be real-time. But … if we
were able to get it sooner maybe we could change
what our interventions were. So, perhaps if we know
we’re going to get typing back in 2-3 days maybe
there’s something in our standardised set that we
might hold off on doing, or do differently. But again
it’s speculation. [90: Ribotyping Trust]
You know, within 48 hours you can wait for a result. I
think anything much longer than that you know you
got a problem… [60: Ribotyping Trust]
However, for some respondents even a 24 hour
turnaround time might be too slow:
At the moment I’d be really nervous around doing
that [holding off action]. I think I’d be more
comfortable around 24 hours. … I mean if we could
have it in 24 hours then you’re gonna say okay you’re
at risk here let’s just wait and see what [the result
shows]. [21: MLVA Trust]
At the same time, hospital staff were clearly aware that
such turnaround times might not be practicable with
current technology:
Well, in an ideal world…..you would want the
turnaround time within a day. I know that’s absolutely
not possible because you would have to grow things…
[10: Ribotyping Trust]
It was also acknowledged that expectations for a more
rapid turn-around time with MLVA might in some cases
not be met because of a necessarily drawn-out testing
process:
And sometimes one loci didn’t work, this didn’t work,
and then you had to repeat it. So, it [time] was very
much marginal difference between the two [MLVA and
ribotyping] [16: MLVA Trust].
Sub-theme: process time in hospital Some respondents
pointed out that a reduced turnaround time in the
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was because of the extended time spent in the hospital
prior to a sample being sent for typing. In the trial, an
average period of two weeks was recorded from identifi-
cation of a PII to receipt of samples in the central typing
laboratory for both test groups. Some hospital staff were
not always aware of the timelines:
By the time the results come back it’s all ancient history.
… when we’re requesting it, it’s quite retrospective
already. They [patients] may be three or four weeks
apart in time and we take a week to pick it [CDI] up. So
by the time you get the typing results back the ward staff
can’t even remember … [9: Ribotyping Trust].
It does sometimes seem to take quite a long time to get
the results back. Some of this [overall time] might be
due to being rather tardy in sending them off in the
first place, I don’t know. I’ve got all that side of things
taken care of by other members of staff so I don’t even
have to initiate it now, and therefore I don’t
necessarily know how timely it’s done [52: Ribotyping
Trust].
Sub-theme: more discriminatory typing information
A far higher percentage of MLVA typing results (41%)
than ribotyping ones (10%) were rated ‘strongly agree’ in
terms of the value recipients placed on their usefulness
in aiding the management of a PII. It appears that, for
MLVA, the more discriminatory information provided
was of more value than any reduction in laboratory
turnaround time:
I’m very much impressed by the sub-type more than the
rapid … .er the rapid perhaps didn’t help very much,
really in terms of management [35: MLVATrust].
Respondents also explained that the value of MLVA
typing information was greatest for more common
ribotypes, where the previous test had been unable to
discriminate, rather than for rarer ribotypes:
I think 30-40% of our strains are 027 s. So if you get a
few 027 s together, and you don’t know the sub-type,
then you think well oh .. we know there’s a whole variety
of things in there … then you’re much more worried
about what’s actually going on. I think when you got a
rare ribotype it’s less, yeah, it [MLVA] doesn’t add that
much more of value…. [14: MLVA Trust].
The biggest [advantage] would be things like the ‘020’
strain because that’s quite common for us to see quite
a few people ‘020’ occasionally. Now sometimes it’s
‘005’ um so now we’ve got say three cases and we don’tknow. It would be nice to go further and say are they
definitely related [65: Ribotyping Trust].
The enhanced ability to discriminate strains was also
viewed as a distinct advantage when there was a larger
outbreak or where an extended incubation period was in
operation:
The sub-typing was something which helps, especially
if there’s a large outbreak..... like in our renal unit last
year, we had five or six cases and it was getting quite
difficult and I think at that point VNTR [MLVA]
really helped to say, there were only two or three which
were a linked sub-type [18: MLVA Trust].
So the incubation period can be quite prolonged…
we’re worried that we might have problems up front
and then people are dispersing all around …. Yes that
typing was really useful, we learnt an awful lot from
that and I’ve never seen something so clear cut as that
[20: MLVA Trust].
Sub-theme: understanding MLVA results Although
the regional laboratory provided an interpretation of
MLVA results, local hospital staff still viewed the new
test information as less straightforward. This meant that,
unlike ribotyping, consideration of MLVA results often
could not be delegated to more junior laboratory staff:
It helps when she draws the [MLVA] trees and
everything, and to actually say yes this is linked, to
beautiful coloured pictures .. yes but for the common
person in the lab and a quick result, and quick
understanding the ribotyping is on your face, you just
know it [36: MLVA Trust].
Yes I don’t think our laboratory staff should [be]
involved in those results of VNTR [MLVA] so it’s just
like a Consultant Microbiologist, a Senior Lab
Manager, or those people, and I think it’s okay for us,
yes…. [47: MLVA Trust].
As it gets more complicated understanding the relatedness
… it gets beyond me. Some of these other typing things. Is
this a true difference or is it something that could have
happened to the organism? [31: MLVATrust].
The ability to distinguish a recurrent CDI infection or
relapse from a new infection was also important, although
interviewees questioned whether even MLVA could distin-
guish this:
And when we say it’s a relapse what is our
confidence that it’s the same strain as they’ve had
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strain, I mean we call it a relapse but how do we
know it’s a relapse of the same strain every time. I
think it’s quite complicated actually, it’s not like
dealing with, you know, MRSA outbreak on a ward
[33: MLVA Trust].
Often what was wanted was a simple ‘yes’ or ‘no’
answer:
Because I mean now we’re here and we’re looking at
people who are doing sequencing and clearly every
germ is different from every other germ, so there’s a
point at which you know you have to say well we don’t
want to know you know there is stuff mutated … but
something that tells us you know that it’s likely to
represent transmission and that it’s unlikely …you
know. [61: Ribotyping Trust].
Sub-theme: confidence in MLVA results In some in-
stances, an MLVA test which indicated that cases were
not linked might be questioned because of worries over
sampling. This reduced confidence in the typing result
and led to action based on the number of CDI cases:
You know sometimes when you get the typing [MLVA]
results back they’re all different but you suddenly have
this massive, four or five cases on a ward and … you
know… I suppose one of the worries is that when
you’ve got somebody with C. diff is it actually you’ve
just got a pure clone of one strain or is it actually
because only one colony is picked off…. and I think so
irrespective of the typing results if you get a blip and
it’s beyond what you expect you go in there hard....
[15: MLVA Trust].
In other instances, if ribotyping and MLVA results dis-
agreed, MLVA might not be believed and an outbreak
recorded, especially for rarer ribotypes:
I’m just trying to remember where ribotyping was
same and VNTR [MLVA] was different and we didn’t
call the outbreak… in fact the reverse has happened.
This year VNTR called it different and ribotyping
called it same and we still called it an outbreak, and
that was ‘005’. Obviously the VNTR doesn’t have
much experience with ‘005’ and we felt that this is
quite unusual to have two on a ward … and then to
have a slightly different VNTR … and we just didn’t
feel confidence in their VNTR typing for that one. So
we’ve felt that it looks clinically as .. as an outbreak
and it fits in with the ribotyping, we will go ahead
with the outbreak, and we called it as an outbreak,
regardless of the VNTR [36: MLVA Trust].Sub-theme: organisation of typing test request The
process within a hospital trust for organising the typing
test request was not necessarily straightforward. In some
trusts, typing requests were managed entirely by a Con-
sultant microbiologist. In these cases, interviewees
appealed for a simpler and less time consuming request
mechanism:
Yes in my organisation, the Biomedical Scientists on
the bench didn’t do the request for the typing. It
actually went to a Consultant which is all very well.
But I would find if I wanted to send three or four off it
would probably take me near on three quarters of an
hour, going in and out of each form. So, yes … the
simpler the requesting mechanism the easier and
perhaps if you are sending three or four could he just
put it on one form or something [62: Ribotyping Trust].
In one trust, the assumption that a senior Consultant
would need to complete requests for MLVA tests was re-
ported to have limited requests to the new typing
service:
I think that I was never really organised enough to,
um we didn’t set up a system so I was talking to one of
my colleagues in another hospital who has used it
extensively. Unfortunately this was very recently and
he said oh that’s fine, and all I had to do was tell the
people in the lab send this one off, and this one off,
and it was done. And I never put that in place, and I
always kind of assumed that it would be totally my
responsibility to do it all and therefore it never got
done… [40: MLVA Trust].
Even in cases where the consultant delegated the test
request process itself to more junior staff, he or she
might still have to support that member of staff in iden-
tifying appropriate cases:
He [junior] will be reviewing the log sheet on a sort of
you know two or three times a week basis and if he
sees pairs coming up, which sometimes I also spot
them myself because I also look at the sheets every
week and I’ll send him an email saying have you
spotted patients A and B or whatever, um so if he sees
those occurring clusters of two on the same ward or
connected to the same ward, within 28 days, he will
then generate the request electronically and notify the
laboratory that they are required to send off the
isolates, so they get going digging out the specimens
and sending them off [53: Ribotyping Trust].
Because of the complex process required to identify
CDI samples for typing, one interviewee suggested that
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sent for typing:
The other thing that I would think would be
potentially beneficial would be just to expand the
typing so that it was done routinely because it’s
quite a lot of effort to try and work out which ones
we should send and which ones we shouldn’t send
[95: Ribotyping Trust].
Theme 3: infection control
As well as exploring factors which influenced the general
usefulness of typing test information, interviewees were
also asked to explain the impact of results on specific IC
measures in greater detail. In particular, they were en-
couraged to explain why typing results did, or did not,
influence IC decisions during PIIs. Certain common
themes emerged in interviews on the relationship be-
tween PCR-ribotyping and MLVA information and deci-
sions about specific IC measures. These demonstrated
the complexity of decision-making and primarily focused
on implementing more targeted control measures over a
period of time.
Sub-theme: ward cleaning Interview groups explained
that, rather than being driven by typing results, cleaning
was routinely triggered by a PII. The process was pre-
defined in some detail in all trusts, especially because
contractors provide ward cleaning services:
We have a fairly organised schedule of cleaning that
happens now anyway. All the commodes get cleaned
with a sporicidal agent routinely; all terminal cleans
are with a sporicidal agent …… and I would say pretty
much all C. diff cases have been isolated as soon as
they’ve been diagnosed and then they’d have a
terminal clean at the end of that period. So, we’re kind
of doing the same thing regardless and the ribotyping
didn’t really influence what we were doing in the end
[50: Ribotyping Trust].
There’s a step change in the cleaning process so we have
enhanced cleaning. Our cleaning contract is with [X:
Company Name] and what we’ve negotiated with them
is if there’s two or more cases on a ward of any infection
then we have enhanced cleaning. That will mean um
they will use a different product but they’d also [do] it
more frequent during the day. [72: MLVATrust].
We do that [enhanced cleaning] for any patient who
has C. diff who is left in a single room with an en-suite
now that low numbers of C. diff. It’s difficult in the
winter when you’ve got flu, competing with it, and
Norovirus. Yes, but we … use the Sterinis [H2O2]machine in the side rooms after they’ve vacated the
rooms [101: Ribotyping Trust].
Table 3 shows that additional cleaning was the most
frequent impact reported. Interviews indicated that the
cleaning action recorded was usually fine tuning of the
pre-defined cleaning protocols. This most often involved
‘enhanced cleaning’: either increased frequency of clean-
ing or a switch of product e.g. to hydrogen peroxide
(H2O2). In the smaller number of cases where typing re-
sults led to planned cleaning measures being stopped
these usually involved not following through with a
planned increase in frequency of cleaning or a change of
cleaning product.
Although cleaning was largely governed by set proto-
cols, more discriminatory information on CDI strains
provided MLVA might trigger a closer subsequent look
at a ward and this could lead to further actions, espe-
cially for wards with vulnerable populations:
But I think where it [MLVA] also helps us … getting that
[sub-type] was you know it’s still lurking there and you
know you’re missing a trick somewhere. Going down
there, lot of things came out, lot of things … because of
the type of patients they were … because these are
people who spend more time in hospital than they do at
home. So they bring in everything bar the kitchen sink.
So that prevents proper cleaning. They then go into a
side room, all the hospital equipment gets clean, they
then come out with all of their contaminated belongings.
And we got rid of all of that [28: MLVATrust].
In cases where typing results confirmed an environ-
mental problem, this could also be useful for negotiating
extra cleaning hours or provide a lever for tackling long-
standing estates issues:
On one occasion, the discovery that two cases who had
the same VNTR [MLVA] type had occupied the same
bed on the ward served as an eye opener to the ward
manager and other staff in relation to the importance
of adequate cleaning [44: MLVA Trust].
And the other thing I was going to say is that the
environmental audit might reveal some estates issues
and if the ward’s on special measures we can use that
as a lever to put pressure on the estates to resolve
some of the issues that they might be loath to resolve
otherwise [98: Ribotyping Trust].
Once you have the ribotype then you can quite
confidently say that this is quite likely to be
environmental, and we do want more cleaning hours
in this ward [64: Ribotyping Trust].
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used in the cleaning contract were shown to have failed
to provide early warning of problems, a new scoring sys-
tem was introduced:
What we used to have, we’ve got [name of cleaning
contractor] in here, but they’ve their own scoring system.
If you look at the cleaning scores in this trust when they
did it, all were between 97 and 99. […] So what was
happening in this trust was that our early warning
system, that there was a problem with the cleaning,
was that we had a C. diff problem not vice versa.
So, we have a vigorous system now where we
performance manage and go around and look on
the wards to make sure that they’re getting decent
ICNA [Infection Control Nurses Association] scores
[30: MLVATrust].
Sub-theme: ward closur Ward closure represents a
major cost to hospitals. Thus, if typing information can
help avoid unnecessary closures this will provide significant
financial benefits. As Table 3 shows, no-one indicated that
a typing test had led to a planned closure being averted,
but some interviewees did think this might be possible:
So, if we have some evidence that these cases are not
linked then probably we wouldn’t close the ward, or …
I mean our actions will be slightly different. Not
necessary everything will be different but this, this
closing the ward is an issue [103: MLVA Trust].
In reality, although more discriminatory MLVA infor-
mation on CDI strains was potentially valuable, in one
case a planned closure was not stopped because of the
persistent nature of the problem:
Somebody came to say to me, you know, why did you
demand that ward was shut when they’re four
different types. I can’t really say. But why do you do it
when they’re all the same type and its on-going. Well,
that’s bloody why, there’s something on that ward
which is gonna do patients in. And we haven’t identified
the force [32: MLVA Trust].
Also, once set in motion, ward closure could be very
difficult to stop. Contradictory typing information might
not avert a planned closure. Especially, if this had been
decided on clinical grounds:
But for instance we, we recently had four cases of C.
diff linked to our intensive care unit, which actually
did lead to the ward being closed. […] The first time
that had ever been closed in its history, and all the
patients decanted. And we requested the VNTR[MLVA], and we managed to get the VNTR back really
fast and they were all different. So actually yes […] we
got 48 hour results back on that and very, very quick.
But even that didn’t prevent the closure. Because the
closure was done on clinical grounds with the number
of cases. [92: Ribotyping Trust].
Table 3 indicates that although typing results were re-
ported to contribute to initiation of ward closures, this
was relatively infrequent. An important factor emerging
in interviews was a dramatic fall in CDI cases which re-
duced the need to close wards for this infection:
I mean the first thing to say is the C. diff numbers in
this trust have fallen like a stone. Now is very, very
different from what we did then when we were right
in the thick of it. It’s hard even to think back to that
time because it’s so different now. Every ward had
got it. If we’d closed - with all the C. diff - the entire
hospital would have just closed down. We got to the
point where we were setting up a separate ward for
C. diff cases. But that was just at the point where
the figures were on the turn. And we never had to do
it [49: Ribotyping Trust].
In interviews it became apparent that the definition of
a ‘ward closure’ could range from complete closure and
major refurbishment, especially if there was evidence of
a persistent problem, to partial closure of consecutive
bays. Typing information mainly contributed to deci-
sions about partial ward closures:
Um I don’t think we actually have ward closures as
such. I mean, normally if we’ve had a PII then one of
our first actions is to try to get hydrogen peroxide
environmental decontamination on that ward… So
although the ward might not have been closed
technically, physically it has been closed because we’re
trying to empty enough beds to be able to um to be
able to clear a bay and then decant patients and then
clear a bay. [42: MLVA Trust].
Sometimes people have closed bays and things but
generally you don’t tend to do that unless you’ve got
a huge problem. Now we did have a problem on one
of the wards that was proved by ribotyping so it’s an
increased incidence and that ended up with the
entire ward being completely gutted and
refurbished. And we haven’t had a problem since
[80: Ribotyping Trust].
Interviews also identified variations between trusts in
the requirement to implement a full ward closure. Such
closures were more likely in hospital settings with limited
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decanted from individual bays was difficult:
We only really did that once [closed ward] during
the time the study was going on. And that was
because we were in the old, it was actually in [Name
of Hospital] where we had almost no isolation
facilities and we had a suspicion that we had on-going
spread that we weren’t able to control. We’ve never done
one yet [since moving to new site] because the numbers
that we’ve had are much smaller and … because we’ve got
much better isolation facilities [87: Ribotyping Trust].
Although staff were aware of the cost to the trust of
ward closures, hospital capacity appeared to be a more
important brake on closures:
And that [ward closure] is an expensive business and
very time consuming [56: Ribotyping Trust].
Closing wards is never an easy business, and as the
wards are, we’re always being encouraged to have less
and less beds, which is leading to huge problems. Yes,
so you’ve got a higher occupancy rate which also has
potential for increasing your C. diff rates, quite
independently. But also its keeping wards closed when
you haven’t got the capacity [82: Ribotyping Trust].
One interviewee pointed out that even if the hospital
policy required a ward to be closed and patients dec-
anted, this might prove to be impossible due to the pres-
sure on hospital beds:
But our policy did say that in general if we thought
that significant transmission had taken place, we
would normally decant and use hydrogen peroxide
vapour. But, it was always left up to management.
Because there were times when [Hospital name] just
you know was really busy and in the winter, and there
were no wards you could decant to. So it wasn’t
always an option [59: Ribotyping Trust].
Once a decision had been made to fully close and deep
clean an entire ward, the logistics and timing of imple-
menting this decision could make the process very slow:
We had to close the [Name] Ward and deep clean the
entire ward and do the fogging, the hydrogen peroxide.
That took more than a month to close before we were
able to do that. […] If you want to clean and if you
actually want to do hydrogen peroxide fogging you
have to clean the entire ward; and to have thirty beds
out of action the only time we could do this was a
Christmas eve [67: MLVA Trust].Sub-theme: audit of practice Table 3 shows that typing
results were more likely to lead to a planned audit of
practice being stopped, rather than a new audit started.
As with ward cleaning, audits were usually set in motion
as soon as a PII was declared. This was part of a battery
of IC measures. Audits tended to be performed on a
regular basis:
So we always do regular audits of practice; the nurses
go round and do those regularly. So we’ve got a very
good infection control team here. So it wouldn’t be
ribotyping really. We do go back in if there’s a PII. But
that is again before the ribotyping comes back, and we
look at practices because we can’t afford to wait then
[81: Ribotyping Trust].
So the way we’ve been operating is that we have a
weekly meeting where we review all of the previous
week’s cases […] and we debate them and look at the
timing, and so on and so forth, and declare whether
it’s a PII or not, for that area. And then various things
flow from that […] the auditing starts and the strain
gets sent for ribotyping so really all of the, all of that
sort of audit, extra cleaning and sending the strains
for typing, that all happens at the same time. So, when
the results come back, the results themselves haven’t
really influenced very much. [93: Ribotyping Trust].
Regardless of whether or not typing confirmed there
had been CDI transmission, this could still be useful in-
formation to either encourage further audit or reassure
staff that their existing practices were robust:
But actually to be able to go to staff and to clinicians
and say do you know what this VNTR [MLVA]
typing is exactly the same as that. That means yeah
that somehow yeah that patient is probably you
know we’ve, we’ve um we’ve been in we’re implicated
in that spread then if you like. Whereas if it’s a
different typing then it just reinforces their practices
or reassures them that their practices are robust
[93: MLVA Trust].
In some cases, typing results were useful in focusing
infection control on specific clinical areas requiring fur-
ther action. Ward antibiotic prescribing policies were
mentioned as an example:
I would say that the knowledge that the ribotyping has
given us, has caused us to concentrate more on the
antibiotic prescribing, type of thing. And so that’s one
of the things we do now if we have say clusters of
three, um is to go into that ward, look at antibiotics
prescribing, do spot-checks on prescribing, communicate
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what’s going on that sort of thing. So it’s enabled us to
shift our focus really [76: Ribotyping Trust].
Well on [Ward name] we restricted, we changed the
whole antibiotic policy for them. They had a totally
different antibiotic policy to everybody else and on the
back of that we changed our policy, our antibiotic policy,
to have a separate section for the vulnerable elderly. […]
So they don’t have a whole garden of antibiotics that
they can choose from [83: Ribotyping Trust].
However, typing results could also be viewed as un-
helpful, especially if they failed to reinforce local good
cleaning practice recommendations:
And we spend a lot of time drilling people about the
importance of commode cleaning so that’s something
that’s happened over the last three or four years I
suppose. And I suppose you could say that the
ribotyping results didn’t really influence that because
they would suggest that perhaps the commodes aren’t
as important as we thought they were …[but]
anybody’s entitled to a clean commode whether or not
it’s going to give them an infection [51: Ribotyping
Trust].
Sub-theme: staff training Table 3 shows that staff train-
ing was very rarely stopped as a consequence of a typing
result. Additional staff training was reported at a similar
frequency to audits of practice. In the latter case, inter-
views demonstrated that extra training was closely
linked to audits, with the audit identifying an underlying
practice issue which required targeted training:
So, for instance, we have one outbreak with ribotype
‘001’ which was in fact confirmed by VNTR [MLVA]
subsequently as all the same strains in ‘001’, and that
was simply failure to isolate the patient index case in
a timely manner. But that led to a whole load of
specific actions and the training of the ward staff by
the ward manager and so forth. So any defects in
training, or additional training, tend to get picked up
in the outbreaks [94: Ribotyping Trust].
Well if the ribotyping has shown a confirmed outbreak
then the root cause analysis - that’s undertaken.
And that leads to an action plan. And one of the
actions may be further education and staff training.
[106: Ribotyping Trust].
Theme 4: indirect benefits
Although most typing results (55%) were reported not to
have any direct impact on IC measures (see Table 3), atthe same time, overall 88% of test-impact forms re-
corded that the recipient ‘agreed’ or ‘strongly agreed’
that the test had aided their management. The inter-
views therefore explored why a value was placed on typ-
ing results even though they had no direct impact on IC
management. The explanations offered centred on more
subtle organisational or indirect clinical benefits.
Sub-theme: organisational culture When asked to ex-
plain, some interviewees described changes to organisa-
tional culture, which were real but difficult to quantify.
It was explained by one interviewee that typing results
had acted like a catalyst on the organisation:
I just think, as I say I can’t tell you what difference it
can make. I mean I’ve told you but it has really made
a difference. When we started to use the VNTR
[MLVA] typing it was a step change for us. And I am
clear we wouldn’t be where we are without it……it has,
it’s been like a catalyst and it enforces, reinforces good
practice, and it exposes poor practice and that for me
is you know it’s about what you actually do isn’t it on
the ward [39: MLVA Trust].
Sub-theme: reassurance/confidence building Inter-
viewees also thought that typing results had increased
professionals’ confidence in their intuitive decision-making.
This reassurance was especially important when dealing
with vulnerable patients such as the elderly:
Um I would think that, for me that would be, it’s the
icing on the cake really. It’s that extra reassurance
that yes they’re all the same sub-type as well .. yes, the
care, the augmented care, because the elderly wards
would be the ones where you’d really want to be sure
that patients are, that patients are being managed
appropriately [84: Ribotyping Trust].
But almost saying well this wasn’t you know a breach
it probably was related to types of person coming in
with it from a Nursing Home or whatever, and our
control measures are still appropriate is so, so helpful
[55: Ribotyping Trust].
Well I suppose just to reiterate just how useful and
fascinating I’ve found it [i.e. typing], and I hope very
much that it’s not on some funding or other that’s
about to be withdrawn because it has certainly given
us a great deal of confidence to say it’s unlikely that
they’ll be the same. [54: Ribotyping Trust].
Sub-theme: epidemiological value The underlying clin-
ical value most commonly mentioned in interviews was
an improved understanding of the epidemiology of C.
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different strains on the wards or in the hospital more
widely was very useful, especially for epidemic strains:
Generally speaking, it’s given us an overview of the
epidemiology… so essentially what it’s told us is that
over time we’ve got rid of the three main epidemic
strains, they have vanished [1: Ribotyping Trust].
We’re worried that .. people are dispersing all around
you know like Trojan Horses round the trust and
certainly we felt that this data…. will help support the
fact that there is a nucleus where contamination
occurs over a period of time and then people got shot
off. [20: MLVA Trust].
So the patients may be linked when they’re not even
on the same ward. But they both were on the same
ward, previously […] let’s say if they’ve both been
through Ward A but then one gets C. diff on Ward B,
and one gets C. diff on Ward C. Previously, we
wouldn’t have linked them at all. But now we are
able to [9: Ribotyping Trust].
What would be useful is matching things not just to
what we think is a problem on a ward because it can
be wider, it is looking outside…because we’re blinkered.
We just focus on that incident that we well know has
got an [extended] incubation period and people who
end up on the ward may have been somewhere else. I
mean I just wondered if a centre had a year’s worth of
data looking through every case whether you’d start
seeing patterns [23: MLVA Trust].
In this context, the more discriminatory power of
MLVA typing results had a clear advantage. This infor-
mation could be helpful in confirming or overturning as-
sumptions based simply on CDI ribotyping patterns:
So when we did have a few ‘027’s, we did a lot of work,
and we thought we’d track them back and we could
explain them. You know for example we said that this
person was next to that person and they were in the
medical assessment unit. And when we eventually got
the sub-typing back it clearly wasn’t right at all. Our
assumptions were wrong [55: Ribotyping Trust].
One interviewee identified the potential for wider use
of more discriminatory MLVA information to examine
transmission routes not just in the hospital, but beyond,
although this has not been undertaken:
If we could actually map the types of the sub-types
across the health-economy we might be able to trackdown well actually no it’s not on the ward, it’s .. it’s at
the bingo down the road or, you know, this community
centre, or whatever [24: MLVA Trust].
Discussion
Qualitative research evidence on the experiences of staff
involved in trials of new diagnostic tests has been
highlighted as important by bodies such as NICE [3], al-
though it remains limited. As an example, evidence on
the practical use of new typing tests for C. difficile in a
real-world hospital context is lacking. Information from
hospital staff who use these tests, particularly evidence
on how typing information influences their infection
control decisions during periods of increased CDI inci-
dence and what broader benefits typing provides, re-
mains a significant gap in the literature. As new rapid
tests with increased discriminatory power to identify
C. difficile strains are developed and promoted it is im-
portant to gather this evidence. The assumption is that
providing such tests will lead to measurable benefits.
However, the actual value of a new test is complex and
will depend not only on what information it provides
and how quickly, but also how this is combined with
other organisational factors [2].
The findings reported here from a trial comparing a
new, more rapid and discriminatory typing test (MLVA)
with slower PCR-ribotyping help to address some of these
questions. In our study, hospital staff highlighted three im-
portant changes in context which had influenced the use
of CDI typing information at grass roots level. The first
was a fall in the incidence of cases, with a 64% drop re-
ported nationally between 2007 and 2010 [26], and linked
to this the fact that typing information had shown that less
than one in three PIIs involved infection transmission. To-
gether this meant fewer instances in which decisions
about implementing IC measures had to be made. In
addition, the introduction of financial fines for confirmed
CDI outbreaks in the UK had increased the perceived
value of MLVA information for the organisation. An in-
creased power to differentiated strains had reduced the
number of outbreaks trusts had to report, and therefore
reduced exposure to the risk of a financial penalties for
the hospital [19].
In terms of direct clinical use of typing results, the pic-
ture emerging from our interviews is one of complex
decision-making and limited flexibility to wait for test
information when faced with a period of increased CDI
incidence. The need for more rapid information is the
most important factor limiting direct test utilisation.
This was true both for existing ribotyping and for more
rapid MLVA. When pressed, staff stated they might be
prepared to wait 2-3 days before implementing IC mea-
sures. But, even the more rapid MLVA test could not
provide results within this time frame. In the period
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fore still automatically triggered by hospital protocols. In
some hospitals these protocols might now even be triggered
by the first CDI case, before a second case was confirmed
and therefore before typing was requested.
In terms of infection control measures, for CDI a
growing evidence base has shown that a number of mea-
sures are effective. The primary measure shown to be ef-
fective in preventing transmission is rapid isolation
(within two-hours). This is known to be the single most
effective intervention to prevent transmission [11]. Inter-
viewees reported that decisions on patient isolation were
now easier to implement because of the lower numbers
of CDI cases and reduced pressure on isolation facilities.
The next most effective measure to prevent transmission
is cleaning. After a few hours, airborne contamination
will have occurred and surfaces will become ‘seeded’
with C. difficile. Following this, any area occupied by a CDI
patient should be cleaned with various cleaning agents and
germicides [27]. In some cases, more expensive dry-mist
hydrogen peroxide decontamination of the whole area may
be required to reduce the number of colony-forming units
[28,29]. In interviews, initial decisions on cleaning were
rarely linked directly to a typing result; hospital protocols
were once again the main driver. But, additional ‘enhanced’
cleaning might be activated following typing information.
Also, where existing cleanliness indicators were shown to
have failed to provide early warning of a problem, a new
scoring system might be introduced [30].
In addition to actions such as isolation and cleaning,
regular audit of compliance with various infection con-
trol policies, including antimicrobial prescribing, are
shown to have an effect on transmission [31]. In the
present study, initial decisions on such audits were sel-
dom influenced by typing; instead these were triggered
by hospital protocols. Interestingly, audits of practice
were the only IC measure where typing results were
more likely to lead to an activity being stopped rather
than initiated. In such cases, typing results might pro-
vide re-assurance that existing practices are robust and
that further audits are unnecessary. Changes to ward
policies (e.g. antibiotic prescribing policies) were also re-
ported as a result of typing information. Extra staff train-
ing, initiated following a typing result, was usually linked
to instances where additional audits had been under-
taken. Test results could also occasionally be viewed as
unhelpful in terms of improving staff practice if an audit
identified that improvements were required but lab re-
sults subsequently indicated that no transmission had
taken place. Expensive decisions on ward closures were
only rarely influenced by a typing result. Typing infor-
mation never stopped a planned closure but might lead
to one being initiated, usually involving partial closure
and cleaning of bays.Any reduction in laboratory turnaround time for CDI
typing tests should be set within the broader context of
the overall hospital testing process. Although MLVA re-
duced typing turnaround time by over 8 days, there was
no impact on the longer period (14 days) between iden-
tification of a PII and receipt of samples in the typing la-
boratory. Furthermore, the requirement to wait up to 28
days for a second CDI case to occur before a PII could
be declared made the overall ‘testing period’ extremely
protracted. Set against these timelines, a reduction of 8
days would have limited influence. At the same time, IC
measures were increasingly being initiated during the 28
day period before a PII was declared and before the
typing test was requested. The initial test used within a
hospital to confirm infection is also important in the
whole chain of testing and infection control. Currently,
the optimum test for initially diagnosing C. difficile in-
fection is being questioned in the UK because the as-
says commonly used in hospitals for toxin detection
have been demonstrated to have poor sensitivity and
specificity [32]. Combination testing has recently been
advocated [33].
In the context describe above, the imperative to wait
for a typing result before making a decision about
whether or when to implement IC measures is reduced,
tipping the balance towards immediate action. Interview
evidence confirmed this, indicating that the main direct
clinical benefits from typing results were refinements to
IC measures already set in motion, or reassurance (after
the event) that correct decisions had been made. This
would appear to offer an explanation for the fact that
the trial could demonstrate no significant impact on the
number of CDI cases in hospitals with access to more
rapid MLVA typing tests. At the same time, MLVA typ-
ing results were four times more likely than ribotyping
to be rated ‘strongly agree’ in terms of their perceived
value in aiding management. However, interviews also
indicated that MLVA results could be complex to under-
stand, not always providing as clear cut an answer as
ribotyping. This meant that consultant microbiologists
were not able to delegate this task to more junior staff
and might themselves even need further advice from the
typing laboratory. In some cases hospital staff reported
that, because of a lack of certainty in the new technol-
ogy, MLVA results which indicated no transmission
might not be believed, perhaps linked to worries over
correct sampling. Finally, the added organisational and
management effort associated with requesting a typing
test (identifying cases occurring within 28 days of each
other and arranging for samples to be extracted and sent
to the regional laboratory) could also act as a barrier. In
one trust, difficulties in setting up an efficient system for
ordering MLVA typing tests had led to underutilisation
of the new service.
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substantive differences between the MLVA and ribotyp-
ing group in direct use of typing results. At the same
time, when asked to describe the value of typing infor-
mation the answer most commonly given was an im-
proved understanding of the underlying epidemiology of
CDI strains in the hospital. This benefit is not, of course,
dependent on the speed of the test result and enhanced
by the ability of MLVA to discriminate between various
sub-types. When asked to compare the more discrimin-
atory information provided by MLVA with ribotyping
this was, as might be expected, thought to be of most
value in the context of common ribotypes where the
added information provided could help confirm whether
transmission had actually occurred. In particular, respon-
dents identified the potential for more discriminatory
MLVA information to be useful when considering patient
movements between wards or beyond the hospital.
Following the introduction of an NHS Ribotyping Net-
work in 2007, C. difficile figures in English hospitals have
declined markedly and deaths associated with CDI have
also decreased. It has been suggested that access to a
ribotyping service may have facilitated better local con-
trol of CDI cases, leading to this decrease [34]. However,
a 2009 report by the National Audit Office (NAO) on
Healthcare Associated Infections in Hospitals in England
found that, although twenty nine per cent of hospital
trusts had managed to reduce CDI by over 50 per cent,
19 per cent of trusts were found to have had an increase
[35]. The NAO reported that leadership, performance
management and clinical practice were important factors
in differentiating trusts.
The methodological challenges associated with per-
formance of qualitative studies alongside randomised
controlled trials, and the associated benefits, are well
documented for complex healthcare interventions, but
not for diagnostic tests [36,37]. In diagnostics, the focus
still remains largely on technical evaluation of test per-
formance. The process of test utilisation and the experi-
ences of staff using the tests are largely ignored. This is
not surprising since in diagnostics even randomised con-
trolled trials evaluating the impact of tests on patient
outcomes are rare [38]. As a result, considerable meth-
odological challenges remain. Even though guidelines
are being developed for broader assessment of the value
of diagnostic studies, these do not yet consider the role
of qualitative research [39]. The main limitation of the
present study is that, although in-depth qualitative data
was collected, this was necessarily dependent on the
views of selected senior staff in a relatively small sample
of hospital trusts. Even so, the main evidence and
themes emerging as described above are consistent.
The evidence from our study highlights the real-world
issues that hospitals face in trying to integrate typing testinformation into their management of possible CDI out-
breaks. Improved control of CDI transmission remains
an economic as well as a clinical imperative. The cost of
C. difficile infection is considerable; it has been esti-
mated as €3 billion/year in the EU [8], with increased
hospital length of stay plus subsequent re-admissions
to hospital as the main cost drivers [40]. The British
Medical Association has concluded that reductions in
hospital-acquired infections such as CDI can only be
achieved through strong organisational commitment
and implementation of policies that are practicable and
effective in prevention and control [31]. This study
shows that strong hospital protocols, used to direct in-
fection control procedures, are in use in NHS hospi-
tals. However, more research is needed to explore how
best to provide a typing service. Particularly relevant is
a need for agreement between hospital trusts and re-
gional laboratory on accessing the service, presentation
of results, and optimum use of typing information.
Conclusions
Although the majority of typing results were considered
to be of value, typing information was reported to have
limited direct impact on infection control measures dur-
ing a PII. The timing of typing results appeared to be a
major limiting factor. Even with a reduction of 8 days
between the delivery of MLVA and ribotyping results,
the turnaround time for both was considered too long.
Implementation of IC measures was driven by hospital
protocols and commenced prior to receiving the typing
result. The MLVA typing service was valued predomin-
antly for the more discriminatory typing information
provided, rather than its increased speed. This provided
benefits for professionals either in terms of reassurance
about decisions already taken or by allowing fine tuning
of infection control measures. The main reason given
for valuing MLVA information was an improved under-
standing of the epidemiology of CDI strains in the hos-
pital. There remains the potential for wider use of typing
information to examine transmission routes. Impact on
organisational culture was more subtle, and difficult to
quantify.
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